New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 24, 2018 - Otsuka announced the FDA approval of Jynarque (tolvaptan), to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
Download PDF
Return to publications
